Profile image
Story Views

Last Hour:
Last 24 Hours:

Multiple Myeloma Drugs Market 2017 Trends, Growth and Forecast to 2021

Monday, February 13, 2017 2:28
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

Publisher’s analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

For more information about this report: .                    

Covered in this report 
The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.
The market is divided into the following segments based on geography: 

Publisher’s report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
-Johnson & Johnson
-Takeda Pharmaceuticals


Request Sample Copy at .                       


Other prominent vendors 
-AB Science
-Acceleron Pharma
-Acetylon Pharmaceuticals
-Adaptimmune Therapeutics
-Alexion Pharmaceuticals
-AmpliMed Corporation
-Array BioPharma
-Benovus Bio
-Biokine Therapeutics
-bluebird bio 
-Bristol-Meyer Squibb
-Calithera Biosciences
-CASI Pharmaceuticals
-Celldex Therapeutics
-Cellectar Biosciences
-Chroma Therapeutics
-Cleave Biosciences
-Dicerna Pharmaceuticals
-Eureka Therapeutics 
-F. Hoffmann-La Roche
-Geron Corporation
-Innate Pharma
-JW Pharmaceutical
-Karyopharm Therapeutics
-Kyowa Hakko Kirin
-Midatech Pharma
-Mirna Therapeutics
-Molecular Partners 
-NOXXON Pharma
-Oncolytics Biotech
-Ono Pharmaceutical 
-Otsuka Pharmaceuticals
-Prothena Therapeutics
-Sevion Therapeutics
-Specialised Therapeutics 
-Spectrum Pharmaceutical
-SymBio Pharmaceuticals
-TaiGen Biotechnology
-Tragara Pharmaceuticals
-Vaxil Therapeutics

Inquire for Report at .                       

Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.